Skip to content
The 2025 BIO International Convention, hosted by the Biotechnology Innovation Organization (BIO), opens June 16 in Boston, bringing together over 20,000 industry leaders from 72 countries.
“Biotechnology is driven by collaboration, and there is no greater place in the world for industry, stakeholder, and advocate partnership than the BIO International Convention,” said John F. Crowley, President & CEO of BIO. “Here, innovators, scientists, patients, and investors come together to turn small ideas into life-saving solutions, and at a time when the world needs big breakthroughs, BIO’s convention is poised to meet the moment and help deliver better, longer lives for people in the U.S. and around the world.”
BIO President & CEO John F. Crowley welcomes attendees to the 2025 BIO International Convention in Boston.
Monday’s theme – “Collaboration can’t wait” – emphasizes the importance of collaboration between companies and between government and industry. With over 62,000 partnering meetings already scheduled over the next four days, expect fruitful collaborations that could lead to the next incredible breakthroughs.
Why collaboration matters right now
It’s fitting that this year’s event takes place in Boston. Massachusetts produces 15% of the U.S. drug development pipeline and employs nearly 117,000 people in high-skilled jobs, write BIO President & CEO John F. Crowley and MassBio President & CEO Kendalle Burlin O’Connell in the Boston Globe.
“But this engine of innovation and economic growth is under threat,” they continue. “Recent federal actions could derail decades of progress. Deep funding cuts to the National Institutes of Health could dim innovation. Food and Drug Administration staffing reductions have already lengthened some review times and increased regulatory costs. Tariffs and other trade barriers threaten to disrupt critical supply chains and increase hospital and health system costs. As a recent MassBio survey points out, amid this uncertainty, venture capital — the lifeblood of early-stage biotechs — is retreating rapidly, with early-stage deal values hitting a four-year low.”
These issues are expected to be hot topics of discussion on Day 1, which begins with a multi-panel session featuring current and former U.S. government officials from the Department of Health and Human Services (HHS), the Department of Defense, the Administration for Strategic Preparedness and Response (ASPR), and more. Meanwhile, Food and Drug Administration (FDA) Commissioner Dr. Martin Makary, M.D., MPH, will speak on Tuesday, June 17.
How to follow BIO 2025
- Bookmark Bio.News for panel recaps, exclusive Q&As, and much more.
- Join the conversation on X and LinkedIn, with hashtag #BIO2025. Watch for exclusive video content and repost-worthy quotes.
- Subscribe to the Bio.News newsletter to get the highlights (and weekly news and features) in your inbox.
